EPO, short for erythropoietin, is a hormone your body naturally produces to control how many red blood cells you make. It acts as a chemical signal between your kidneys and your bone marrow, ramping up red blood cell production whenever your body detects that oxygen levels are dropping. Synthetic versions of EPO have been used medically since 1989 to treat severe anemia, and they became infamous in the 1990s and 2000s as performance-enhancing drugs in endurance sports like cycling.
How Your Body Makes EPO
Most of your circulating EPO comes from specialized cells in the outer layer of your kidneys. These cells act like oxygen sensors. When oxygen levels in your blood drop, even modestly, these kidney cells flip a molecular switch and start producing EPO. The trigger is a protein called HIF-2, which activates under low-oxygen conditions and directly turns on the EPO gene. This system is remarkably sensitive: depending on how severe the oxygen drop is, your body can ramp EPO production up by several hundred-fold.
Your liver and brain also produce small amounts of EPO, and the liver can step in as a backup producer if the kidneys fail. In a healthy person, normal blood levels of EPO fall between 2.6 and 18.5 milliunits per milliliter. That baseline level fluctuates naturally. Traveling to high altitude, for example, triggers the same oxygen-sensing pathway and increases EPO production, which is why athletes sometimes train at elevation to boost their red blood cell count.
What EPO Does in Your Body
Once EPO enters the bloodstream, it travels to the bone marrow and binds to receptors on young, immature red blood cell precursors. This binding does two critical things: it prevents these precursor cells from dying off (a process called apoptosis) and it stimulates them to multiply and mature into functional red blood cells. More red blood cells means more hemoglobin, which means your blood can carry more oxygen to muscles and organs.
This feedback loop is elegant in its simplicity. Low oxygen triggers EPO release, EPO boosts red blood cell production, more red blood cells deliver more oxygen, and the oxygen-sensing cells in the kidneys dial EPO production back down. The whole cycle keeps your blood oxygen levels in a tight, healthy range without any conscious effort on your part.
Medical Uses of Synthetic EPO
The first synthetic version of EPO, called epoetin alfa, was approved by the FDA on June 1, 1989 for treating anemia in people with chronic kidney disease. Because damaged kidneys can’t produce enough EPO on their own, patients on dialysis often become severely anemic. Synthetic EPO was a major breakthrough for these patients, replacing what their kidneys could no longer make.
Since then, approved uses have expanded. Synthetic EPO is now used to treat anemia caused by cancer chemotherapy (approved in 1993), anemia related to HIV/AIDS, anemia in premature infants, and to reduce the need for blood transfusions before elective surgery. All of these conditions share the same basic problem: too few red blood cells, leading to fatigue, weakness, and shortness of breath. The most well-known brand names are Epogen and Procrit.
Risks and Side Effects
Synthetic EPO isn’t without danger, particularly when pushed to high levels. The most significant risk is blood clots. Venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism, is the most common serious cardiovascular side effect. Because EPO increases the number of red blood cells, it thickens the blood. Thicker blood flows more slowly and clots more easily, which can lead to blockages in veins or arteries.
Other cardiovascular risks include high blood pressure, heart failure, irregular heart rhythms, and arterial clots that can cause heart attacks or strokes. These risks climb sharply when EPO is dosed aggressively to push hemoglobin levels higher than necessary, or when a patient already has poorly controlled blood pressure. This is why medical use involves careful monitoring and modest dosing targets, aiming to raise red blood cell counts just enough to relieve symptoms rather than pushing them into the high-normal range.
EPO in Sports and Doping
EPO became the drug of choice for endurance athletes because it directly increases the body’s ability to deliver oxygen to working muscles. Systematic reviews of controlled studies show that synthetic EPO significantly increases both hematocrit (the percentage of blood volume occupied by red blood cells) and VO2 max (the maximum amount of oxygen your body can use during exercise). Higher VO2 max translates directly to better endurance performance, longer time to exhaustion, and greater maximal power output.
The improvements show up across low, medium, and high doses, though the risks scale up alongside the benefits. Athletes who abused EPO in the 1990s, most notoriously in professional cycling, were essentially giving themselves the cardiovascular risk profile of a patient overdosing on a prescription drug. Thickened blood in a dehydrated athlete during intense exertion is a dangerous combination, and EPO abuse has been linked to deaths in competitive cycling.
The World Anti-Doping Agency banned EPO and developed two main strategies to catch cheaters. The first is direct urine testing that can distinguish synthetic EPO from the natural hormone. The second is the Athlete Biological Passport, a longitudinal tracking system that monitors each athlete’s blood values over time and flags suspicious changes. In a controlled study of recreational athletes given EPO, the passport system flagged abnormal results in 49% of samples collected during the main dosing phase and continued detecting anomalies as late as 70 days after the first injection. Microdosing, a strategy some athletes use to stay under the radar, still triggered flags in 24% of samples. Only a single false positive appeared across all samples from athletes given a placebo, suggesting the system is quite specific.
Why Kidney Disease Makes EPO So Important
The connection between EPO and the kidneys explains one of the most common complications of chronic kidney disease. As kidney tissue deteriorates, the oxygen-sensing cells that produce EPO are gradually lost. The result is a steady decline in red blood cell production that worsens as kidney function drops. By the time a patient needs dialysis, anemia is almost universal. The fatigue and exercise intolerance that come with it are often among the most debilitating symptoms of kidney failure, sometimes more so than the kidney disease itself.
Synthetic EPO transformed the quality of life for these patients when it arrived in 1989. Before that, many dialysis patients required frequent blood transfusions, which carry their own risks including iron overload and immune sensitization that can make future organ transplants harder. EPO therapy doesn’t fix the underlying kidney problem, but it restores the hormonal signal that the kidneys can no longer send, allowing the bone marrow to do its job again.